LGVN
Longeveron Inc.Company Information
- Company Name
- Longeveron Inc.
- CIK
- CIK0001721484
- Category
- <br>Emerging growth company
- Ticker: Exchange
- LGVN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- LGVN
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-08-11
- Last sale
- 2025-05-30
- Shares purchased (TTM)
- 23,532
- Shares sold (TTM)
- 19,500
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 4,704,595
- Shares outstanding
- 31,377,630
- Ownership
- 14.99%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- -8.84%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Class A | 0 | 0 | 0 | 20 | -13 | 13 | 0 | 10 | 1 | 2 | 0 | 0 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | - | - | - | -0 | -0 | 0 | - | -0 | ||||||
| Common Class B | -0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | ||||||
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 10 | 16 | 5 | 9 | 10 | 14 | 19 | 23 | 12 | 2 | 5 | 2 | ||||||
| Marketable Securities Current | - | - | - | - | - | - | 0 | 0 | - | 0 | 0 | 2 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 11 | 17 | 5 | 10 | 11 | 15 | 20 | 24 | 13 | 4 | 6 | 5 | ||||||
| Property Plant And Equipment Net | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 3 | 3 | ||||||
| Intangible Assets Net Excluding Goodwill | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 15 | 21 | 10 | 16 | 17 | 21 | 26 | 30 | 19 | 10 | 12 | 12 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Accrued Liabilities Current | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | ||||||
| Loans Payable Current | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Deferred Revenue Current | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | ||||||
| Contract With Customer Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 1 | - | ||||||
| Other Liabilities Current | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 4 | 4 | 4 | 5 | 3 | 3 | 3 | 3 | 3 | 5 | 4 | 3 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Liabilities Noncurrent | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Liabilities | 5 | 5 | 5 | 6 | 4 | 4 | 4 | 4 | 4 | 7 | 5 | 5 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital | 153 | 153 | 138 | 137 | 132 | 132 | 131 | 131 | 116 | 92 | 92 | 86 | ||||||
| Treasury Stock Value | - | - | - | - | - | - | - | - | - | - | - | -0 | ||||||
| Retained Earnings Accumulated Deficit | -143 | -137 | -132 | -127 | -120 | -115 | -110 | -106 | -101 | -89 | -85 | -79 | ||||||
| Stockholders Equity Note Subscriptions Receivable | - | - | - | - | - | - | 0 | 0 | - | - | -0 | - | ||||||
| Stockholders Equity | 10 | 16 | 6 | 10 | 13 | 17 | 22 | 26 | 15 | 3 | 7 | 7 | ||||||
| Liabilities And Stockholders Equity | 15 | 21 | 10 | 16 | 17 | 21 | 26 | 30 | 19 | 10 | 12 | 12 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialLongeveron Inc. (LGVN) — SEC Financial Statements & Analysis
Longeveron Inc. (LGVN) is a pharmaceutical preparations company, incorporated in DE. Longeveron Inc. trades on Nasdaq as: LGVN. Longeveron Inc. (LGVN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Longeveron Inc. carries a market cap of $220.58M, a P/E ratio of -9.40x, a P/B ratio of 21.21x, a P/S ratio of 185.83x, an enterprise value of $210.51M, and an EV/EBITDA multiple of -9.30x. On profitability, it posts a gross margin of 69.76%, an operating margin of -1992.84%, a net margin of -1977.59%, a Return on Equity (ROE) of -203.61%, a Return on Assets (ROA) of -145.64%, and a Return on Invested Capital (ROIC) of -1744.34%. Per share, it reports EPS of $-0.75, diluted EPS of $-0.75, free cash flow per share of $-0.66, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -42.74% year-over-year, net income growth of -13.67% year-over-year, and EPS growth of -58.69% year-over-year. On the balance sheet, it maintains a current ratio of 2.63x, a quick ratio of 2.35x, working capital of $7.02M, a debt-to-equity ratio of 0.49x, a debt ratio of 0.33, an interest coverage ratio of -14.91x, free cash flow of $-20.62M (TTM), and net debt of $-10.08M. Figures sourced from SEC EDGAR.
- Market Cap
- $220.58M
- P/E TTM
- -9.40x
- EPS TTM
- $-0.75
- P/B TTM
- 21.21x
- ROE TTM
- -203.61%
- ROA TTM
- -145.64%
- Debt To Equity
- 0.49x
- Free Cash Flow TTM
- $-20.62M
- Net Revenue TTM Growth 1Y
- -42.74%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Longeveron Inc. in?
Longeveron Inc. (LGVN) operates in the Pharmaceutical Preparations industry.
What exchange does LGVN trade on?
Longeveron Inc. (LGVN) trades on the Nasdaq.
Where is Longeveron Inc. incorporated?
Longeveron Inc. is incorporated in DE.
When was Longeveron Inc. (LGVN)'s most recent SEC filing?
Longeveron Inc. (LGVN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is LGVN's market cap?
Longeveron Inc. (LGVN) has a market capitalization of $220.58M as of 2026-06-30.
What is LGVN's EPS (earnings per share)?
Longeveron Inc. (LGVN)'s trailing twelve month EPS is $-0.75 as of 2026-06-30.
What is LGVN's ROE (return on equity)?
Longeveron Inc. (LGVN)'s trailing twelve month Return on Equity (ROE) is -203.61% as of 2026-06-30.
What is LGVN's ROA (return on assets)?
Longeveron Inc. (LGVN)'s trailing twelve month Return on Assets (ROA) is -145.64% as of 2026-06-30.
What is LGVN's ROIC (return on invested capital)?
Longeveron Inc. (LGVN)'s trailing twelve month Return on Invested Capital (ROIC) is -1744.34% as of 2026-06-30.
What is LGVN's EV/EBITDA?
Longeveron Inc. (LGVN)'s trailing twelve month EV/EBITDA is -9.30x as of 2026-06-30.